CanSino Biologics

Focus: CanSino Biologics is a China-based vaccine specialist focused on infectious diseases, with a robust pipeline spanning COVID-19, pneumococcal, and routine immunization programs. The company operates from Tianjin and maintains active clinical development across multiple therapeutic areas.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About CanSino Biologics

AI assessmentNot Hiring

No open roles listed right now. Follow CanSino Biologics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

15 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Recombinant Novel Coronavirus Vaccine

COVID-19

N/A

Clinical Trials (1)

NCT04916886A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.

N/A

Help build intelligence for CanSino Biologics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a deep vaccine pipeline with 20 active programs across Phase 1-4, including 9 Phase 3 programs with near-term regulatory potential
Specialization in high-impact infectious disease vaccines addressing large global markets (COVID-19, pneumococcal, meningococcal, polio)
Exposure to recombinant and mRNA vaccine platform technologies with multiple Phase 2-4 candidates in parallel development

Watch Out For

Zero current active job openings suggests minimal hiring momentum or organizational restructuring constraints
Lack of disclosed financial, H1B sponsorship, and publication data limits visibility into R&D capacity, stability, and company culture

Generated by Claude from CanSino Biologics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Tuberculosis

Phase 1

Clinical Trials (1)

NCT06732583A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years

Phase 1

Diphtheria,Tetanus and Acellular Pertussis

Diphtheria

Phase 1

Clinical Trials (1)

NCT04099303Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .

Phase 1

Recombinant Trivalent Poliomyelitis Vaccine

Poliomyelitis

Phase 1

Clinical Trials (1)

NCT06101173A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults

Phase 1

Adsorbed Acellular Pertussis

Diphtheria, Tetanus and Acellular Pertussis

Phase 1

Clinical Trials (1)

NCT07203755Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

Phase 1

COVID-19 mRNA vaccine

COVID-19

Phase 1

Clinical Trials (1)

NCT05373485Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

Phase 1

Tetanus, Reduced Diphtheria and Acellular Pertussis

Diphtheria

Phase 1

Clinical Trials (1)

NCT06056050A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)

Phase 1

Protein based pneumococcal vaccine

Pneumonia

Phase 1

Clinical Trials (1)

NCT04087460Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine

Phase 1

PBPV

Pneumonia

Phase 1

Clinical Trials (1)

NCT05622942Clinical Trial of Recombinant Pneumococcal Protein Vaccine

Phase 1

TTVA

Tetanus

Phase 1

Clinical Trials (1)

NCT06123663A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

Phase 1

Recombinant Zoster Vaccine

Herpes Zoster

Phase 1

Clinical Trials (1)

NCT05991427A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years

Phase 1

Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine

Haemophilus Influenzae Type B Infection

Phase 1

Clinical Trials (1)

NCT06621654Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine

Phase 1

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）

Pneumococcal Infections

Phase 1

Clinical Trials (1)

NCT04100772Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above

Phase 1

Recombinant Novel Coronavirus Vaccine

COVID-19

Phase 1

Clinical Trials (1)

NCT04313127Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults

Phase 1

Recombinant Trivalent Poliomyelitis Vaccine

Poliomyelitis

Phase 1/2

Clinical Trials (1)

NCT06577298A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers

Phase 1/2

Recombinant Novel Coronavirus Vaccine

COVID-19

Phase 1/2

Clinical Trials (1)

NCT04840992Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

Phase 1/2

Recombinant Novel Coronavirus Vaccine

COVID-19

Phase 1/2

Clinical Trials (1)

NCT04398147Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

Phase 1/2

COVID-19 mRNA vaccine

COVID-19

Phase 2

Clinical Trials (1)

NCT05373472Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

Phase 2

Recombinant Novel Coronavirus Vaccine

COVID-19

Phase 2

Clinical Trials (1)

NCT04566770A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Phase 2

Recombinant novel coronavirus vaccine

COVID-19

Phase 2

Clinical Trials (1)

NCT04341389A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)

Phase 2

Recombinant Novel Coronavirus Vaccine

Covid19

Phase 2

Clinical Trials (1)

NCT05005156Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV

Phase 2

Ad5-nCov

COVID-19 Vaccine

Phase 2

Clinical Trials (1)

NCT05293223Phase IIB Study of Recombinant Novel Coronavirus Vaccine

Phase 2

Tetanus, Reduced Diphtheria and Acellular Pertussis

Diphtheria

Phase 2/3

Clinical Trials (1)

NCT06708286A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)

Phase 2/3

PCV13i

Pneumococcal Infections

Phase 3

Clinical Trials (1)

NCT07017777A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

Phase 3

MCV4

Meningococcal Meningitis

Phase 3

Clinical Trials (1)

NCT06226714A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Phase 3

Diphtheria, Tetanus and Acellular Pertussis

Phase 3

Clinical Trials (1)

NCT06857370Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine

Phase 3

Diphtheria, Tetanus and Acellular Pertussis

Phase 3

Clinical Trials (1)

NCT05951725A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

Phase 3

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）

Pneumococcal Infections

Phase 3

Clinical Trials (1)

NCT04841369Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

Phase 3

Recombinant COVID-19 vaccine

COVID-19

Phase 3

Clinical Trials (1)

NCT05124561Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)

Phase 3

Recombinant Novel Coronavirus Vaccine

COVID-19

Phase 3

Clinical Trials (1)

NCT05169008A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents

Phase 3

Recombinant COVID-19 vaccine

COVID-19

Phase 3

Clinical Trials (1)

NCT05517642IH Convidecia as Second Booster Dose Against Breakthrough Infections

Phase 3

TTVA

Tetanus

Phase 3

Clinical Trials (1)

NCT06120751A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

Phase 3

Recombinant Novel Coronavirus Vaccine

Covid19

Phase 3

Clinical Trials (1)

NCT04540419Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

Phase 3

Bivalent Recombinant COVID-19 Vaccine

COVID-19

Phase 3

Clinical Trials (1)

NCT05442684A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine

Phase 3

MCV4

Epidemic Meningitis

Phase 3

Clinical Trials (1)

NCT06011200A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population

Phase 3

Recombinant Novel Coronavirus Vaccine

COVID-19

Phase 3

Clinical Trials (1)

NCT04526990Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

Phase 3

batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine

Meningococcal Meningitis

Phase 3

Clinical Trials (1)

NCT06131554A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Phase 3

MCV4

Meningococcal Meningitis

Phase 3

Clinical Trials (1)

NCT06700148A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds

Phase 3

MCV4

Epidemic Meningitis

Phase 4

Clinical Trials (1)

NCT05935176Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)